Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21626580 | 0.86 | NR3C1 (0.38) | NR3C1PGRNR3C2ARLRRK2 | |
| SCHEMBL16138211 | 0.84 | F11 (0.45) | NR3C1PGRNR3C2ARF11 | |
| SCHEMBL17629385 | 0.83 | SCN8A (0.42) | NR3C1PGRNR3C2ARLRRK2 | |
| SCHEMBL21626576 | 0.83 | ALDH1A1 (0.39) | NR3C1PGRNR3C2ARLRRK2 | |
| SCHEMBL16115826 | 0.82 | F11 (0.39) | F11LRRK2KMT2APOLBLMNA | |
| SCHEMBL18327656 | 0.81 | NR3C1 (0.44) | NR3C1PGRNR3C2ARF11 | |
| SCHEMBL28506695 | 0.81 | PDGFRB (0.36) | NR3C1PGRNR3C2ARLRRK2 | |
| SCHEMBL23386428 | 0.80 | NR3C1 (0.43) | NR3C1PGRNR3C2ARLRRK2 | |
| SCHEMBL17633174 | 0.79 | F11 (0.44) | NR3C1PGRNR3C2ARF11 | |
| SCHEMBL19945739 | 0.77 | ALDH1A1 (0.47) | F11SCN8ASCN10AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221648-A | Factor XIa small molecule inhibitor and preparation method and application thereof | 合肥工业大学智能制造技术研究院 | 2024-06-21 | — | — | CN | disclosed |
| CN-112028877-B | Alkoxy pyridone compound and preparation method and application thereof | 江西济民可信集团有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-112028877-A | Alkoxy pyridone compound and preparation method and application thereof | 江西济民可信集团有限公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-3197872-B1 | (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| EP-3197872-B1 | (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-10167280-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-01 | — | — | US | disclosed |
| EP-3197873-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-12 | — | — | US | disclosed |
| EP-3197872-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197873-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046166-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046166-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046164-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046164-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167280-B2 | Substituted oxopyridine derivatives | OGFOD1, PNPO, VASP | NR3C1 3346/4885PGR 2354/4885NR3C2 2150/4885 |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, PNPO, VASP | NR3C1 3346/4885PGR 2354/4885NR3C2 2150/4885 |
| US-20170291892-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, PNPO, VASP | NR3C1 3346/4885PGR 2354/4885NR3C2 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.